TELA Bio TELA 深 沪
交易中 12-19 10:53:23 美东时间
1.13
-0.010
-0.88%
华盛通- 最 高1.13
- 今 开1.13
- 成交量 4235股
- 最 低 1.13
- 昨 收 1.14
- 总市值 4476.65万
- 52周最高 3.0994
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 0.8645
- 委 比 34.43%
- 总股本 3961.64万
- 历史最高 23.545
- 量 比 0.20
- 振 幅 0.00%
- 历史最低 0.8645
- 每 手 1
- 风险率 0.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio, Inc. announces inducement grants of 3,600 restricted stock units (RSUs) to three newly-hired employees. The RSUs, granted on December 9, 2025, vest annually over four years and were awarded under Nasdaq Rule 5635(c)(4) to induce employment.
12-12 21:05
美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
12-02 09:50
Lake Street Maintains Buy on TELA Bio, Lowers Price Target to $3
Lake Street analyst Frank Takkinen maintains TELA Bio (NASDAQ:TELA) with a Buy and lowers the price target from $6 to $3.
12-02 01:03
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
11-19 11:01
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio授予17名新员工30,200股限制性股票单位及一名员工25,000股期权，授予日为2025年11月10日。此激励基于纳斯达克规则，作为就业补偿的一部分。期权行使价为$1.19，有效期10年，第一年25% vest，剩余36个月每月 vest。限制性股票单位四年内年度 vesting。
11-17 21:05
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
11-17 10:49
TELA Bio Secures $70M Loan for Growth Initiatives
TELA Bio ( ($TELA) ) just unveiled an announcement. On November 13, 2025, TELA ...
11-15 06:12
Citizens Maintains Market Outperform on TELA Bio, Lowers Price Target to $5
Citizens analyst David Turkaly maintains TELA Bio (NASDAQ:TELA) with a Market Outperform and lowers the price target from $7 to $5.
11-14 23:29
TELA Bio FY2025 Revenue expected to be more than $80.388M vs $85.416M Est
TELA Bio (NASDAQ:TELA) FY2025 Revenue expected to be more than $80.388M vs $85.416M Est
11-14 06:10
TELA Bio Prices ~$13M Common Stock, Pre-Funded Offering
TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the pricing of an underwritten registered direct offering of
11-14 05:23
